← Aligos Therapeutics, Inc. (ALGS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aligos Therapeutics, Inc. (ALGS)
Biological Products, (No Diagnostic Substances) · market cap $35M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Aligos Therapeutics (ALGS) is a ~70-person clinical-stage biotech focused on viral and liver diseases, with a market cap of ~$288M and two Phase 2 assets: ALG-000184 for chronic hepatitis B and ALG-055009 for NASH. The company carries a critical financial constraint: only $30M in cash representing roughly 3.9 months of runway, against an annual R&D burn rate in the $69–70M range. The next binary event is an estimated Phase 2 readout for ALG-000184 around March 2027.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 2 · ALG-000184imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ALG-000184 | Phase 2 | Chronic Hepatitis B Infection |
| ALG-055009 | Phase 2 | NASH |
Price & technical context
3-month
-5.3%
6-month
-30.5%
12-month
-46.2%
52-wk range
$4.08–$13.30
vs 50-day MA
-4.1%
vs 200-day MA
-17.4%
Realized vol
86.7%
Max drawdown
-91.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALGS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.